Editas Medicine, Inc. (0IFK.L)
- Previous Close
1.6100 - Open
1.6000 - Bid --
- Ask --
- Day's Range
1.6000 - 1.7294 - 52 Week Range
1.6000 - 11.7900 - Volume
3,585 - Avg. Volume
5,909 - Market Cap (intraday)
82.798M - Beta (5Y Monthly) 2.16
- PE Ratio (TTM)
-- - EPS (TTM)
-2.7300 - Earnings Date May 6, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
www.editasmedicine.com246
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Recent News: 0IFK.L
View MorePerformance Overview: 0IFK.L
Trailing total returns as of 5/4/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0IFK.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0IFK.L
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-35.52%
Return on Equity (ttm)
-98.10%
Revenue (ttm)
32.31M
Net Income Avi to Common (ttm)
-237.09M
Diluted EPS (ttm)
-2.7300
Balance Sheet and Cash Flow
Total Cash (mrq)
269.91M
Total Debt/Equity (mrq)
26.09%
Levered Free Cash Flow (ttm)
-121.09M